肾脏相关性状多基因风险评分的范围综述
该范围综述检索PubMed、Embase、Scopus和Web of Science,纳入104项研究、129个评分或评估,系统梳理肾脏相关性状与疾病的多基因风险评分(PRS)和遗传风险评分(GRS)的构建与效能。研究最集中于慢性肾脏病(CKD,n=43)和估算肾小球滤过率(eGFR,n=18),主要挑战为 ancestry 失衡、CKD增量预测效能有限及推导性状与评估结局不匹配。
要点
- PRS/GRS在肾脏病学的临床价值取决于具体应用场景。
- 研究集中在CKD与eGFR,其他肾脏结局研究较少。
- 需改善人群多样性、表型定义与方法学标准化。
核心结论
- 当前证据提示PRS和GRS在肾脏病学中的临床效用取决于具体情境。
- 改善多样性、表型定义和方法学标准化对提升转化潜力至关重要。
研究设计与样本
- 2025年4月检索PubMed、Embase、Scopus和Web of Science的同行评议文章与预印本。
- 遵循PRISMA-ScR指南开展范围综述,纳入开发或评估肾脏相关性状PRS和GRS的研究。
- 共识别1947条记录,104项研究符合纳入标准,涵盖129个独特评分或评估。
主要发现
- 研究最多的性状为慢性肾脏病(CKD,n=43)和估算肾小球滤过率(eGFR,n=18)。
- 白蛋白尿、eGFR斜率、终末期肾病(ESKD)、急性肾损伤(AKI)及CKD特定亚组仅有少数研究评估。
- 主要挑战包括祖先人群明显失衡(以欧洲人群为主)、CKD增量预测效能有限及推导性状与评估结局频繁不匹配。
临床怎么用
- 解读肾脏PRS/GRS时应结合其推导人群与目标结局,避免跨情境外推。
- 现有证据尚不足以支持在肾内科常规临床决策中普遍使用PRS/GRS。
局限性
- 以欧洲人群为主,其他祖先人群证据不足。
- CKD增量预测效能有限,且推导性状与评估结局常不匹配。
- 仅检索至2025年4月,纳入同行评议文章与预印本。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Large-scale genome-wide association studies (GWAS) have identified numerous loci associated with various diseases and traits, enabling the development of polygenic risk scores (PRS) and genetic risk scores (GRS) that capture cumulative effects of variants. Although these scores have been applied in nephrology, no review has systematically evaluated their implementation or performance. This review aimed to summarize the current landscape of PRS and GRS related to kidney traits and diseases. METHODS: In April 2025, we searched PubMed, Embase, Scopus, and Web of Science for peer-reviewed articles and preprints following the Preferred Reporting Items for Systematic Reviews and Meta-Analysis extension for Scoping Review guidelines. Studies were included if they developed or evaluated PRS and GRS for kidney-related traits. Data on study characteristics, score construction, and performance metrics were extracted. RESULTS: Of the 1947 records identified, 104 met the inclusion criteria, encompassing 129 unique scores or evaluations. The most frequently studied traits were chronic kidney disease (CKD, n = 43) and estimated glomerular filtration rate (eGFR, n = 18). Additional outcomes such as albuminuria, eGFR rate slope, end-stage kidney disease (ESKD), acute kidney injury (AKI), and specific subgroups of CKD, were evaluated in a few studies. The key challenges include a marked ancestry imbalance, with a predominance of European populations, modest incremental predictive performance for CKD, and frequent mismatches between derivation traits and evaluated outcomes. CONCLUSION: Current evidence suggests that the clinical utility of PRS and GRS in nephrology depends on the context. Improved diversity, phenotype definition, and methodological standardization are essential for enhancing translational potential.
引用
- Sugawara Y, Ito K, Iwagami M, et al. Scoping Review of Polygenic Risk Scores in Kidney-Related Traits. Kidney Int Rep. 2026. PMID: 42436695. doi:10.1016/j.ekir.2026.106646
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。